首页> 外文期刊>Life sciences >Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals
【24h】

Chronic treatment with anti-GIPR mAb alone and combined with DPP-4 inhibitor correct obesity, dyslipidemia and nephropathy in rodent animals

机译:单独用抗GIPR MAb进行慢性处理,并将DPP-4抑制剂与啮齿动物动物中的血脂血症和肾病联合

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Glucose-dependent insulinotropic polypeptide receptor (GIPR) has been identified as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO). Therefore, we developed the anti-GIPR antagonistic monoclonal antibody (mAb) alone and in combination with DPP-4 inhibitor as potential therapeutic strategy for treating obesity and dyslipidemia based on this genetic evidence.
机译:目的:葡萄糖依赖性促胰岛素多肽受体(GIPR)已被确定为肥胖的促发因素,GIPR基因敲除小鼠可预防饮食诱导肥胖(DIO)。因此,基于这一遗传证据,我们开发了抗GIPR拮抗性单克隆抗体(mAb),并与DPP-4抑制剂联合使用,作为治疗肥胖和血脂异常的潜在治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号